Genetic Technologies gets tough

By Kate McDonald
Monday, 14 July, 2008


Genetic Technologies (ASX: GTG) will enforce its exclusive rights to perform diagnostic testing of the BRCA1 and BRCA2 breast cancer genes in Australia and New Zealand.

The company has been paying ongoing licence fees to Myriad Genetics for exclusive rights to perform diagnostic testing but has been allowing other service providers to perform BRCA testing for the last five years.

Genetic Technologies said in a statement it was now enforcing those exclusive rights, preventing several laboratories throughout the country from performing the test.

It said it had invested several million dollars in a high-throughput molecular diagnostic laboratory and had reduced turnaround time to four weeks.

Related Articles

Heat-induced heart disease is killing Australians

Hot weather is responsible for an average of almost 50,000 years of healthy life lost to...

Call for greater diversity in genomics research

A gene variant common in Oceanian communities has been misclassified as a potential cause of...

Better semen quality linked to men living longer

Men with the best semen quality can expect to live two to three years longer, on average, than...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd